首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126464

心臟遺傳學檢測市場：策略性洞察與預測（2026-2031 年）

Cardiogenetic Testing Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月17日 | 出版商:

Knowledge Sourcing Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計心臟基因檢測市場將以 11.9% 的複合年成長率成長，從 2026 年的 47.6 億美元成長到 2031 年的 130.6 億美元。

全球心臟基因檢測市場正快速擴張，這主要得益於基因組學在循環系統醫學領域日益廣泛的應用以及人們對遺傳性心臟病認知的不斷提高。心臟基因檢測能夠識別與遺傳性心血管疾病相關的致病基因突變，這些疾病包括心肌病、遺傳性心律不整症候群、遺傳性高膽固醇症以及影響循環系統的結締組織疾病。該市場涵蓋檢查室特異性檢測、標靶基因panel、全EXOME定序、全基因測序、生物資訊學平台、解讀軟體以及遺傳諮詢服務，這些服務能夠全面支持臨床決策。隨著心血管專家意識到僅憑表現型評估往往不足以區分遺傳性和後天性心臟病，市場需求正在不斷成長。分子層面的早期確診有助於制定個人化的監測策略，指導治療性介入，並實現家族層面的級聯檢測。監管機構和醫學專業協會持續強調檢查室品質的標準化、分析的有效性以及實證臨床報告，從而增強了人們對基因組診斷的信心。醫療機構正日益將多學科遺傳諮詢融入心血管疾病診療中，確保檢測結果不僅作為獨立的診斷觀察，還能用於疾病的長期管理。這一發展趨勢進一步提升了心臟基因檢測在全球精準醫療計畫中的策略重要性。

市場促進因素

精準心臟醫學臨床應用拓展

精準循環系統醫學將基因組資訊與傳統心血管評估結合，以改善診斷和治療方案。由於遺傳性心血管疾病的臨床表現往往存在重疊，使傳統診斷變得複雜，因此醫療機構擴大採用基因檢測。分子層面的早期確診可以降低診斷的不確定性，同時支持個人化的後續觀察和治療方案。診斷檢查室正在擴展其心血管專科檢測項目，以滿足日益成長的臨床需求。基因組學在心血管診療中的日益普及，正在鞏固其在三級醫療機構和專科心臟中心的長期應用。

以家庭為基礎的級聯篩檢的需求日益成長

遺傳性心血管疾病常在同一家族的多代人中發生。由於識別家族中的致病突變有助於在症狀出現前進行預防性監測，醫療專業人員建議進行級聯基因檢測。隨著專業學會強調基於家族的遺傳性心臟病風險評估，臨床實務中的相關意識也不斷提高。診斷檢測實驗室正在開發簡化的檢測流程，以方便對多個家庭成員篩檢。早期識別具有遺傳易感性的個體，可以透過積極的臨床管理來減輕疾病負擔。

定序技術的不斷進步

定序技術在分析靈敏度、處理能力和成本效益方面持續提升。由於次世代定序平台能夠比傳統的序貫檢測方法更有效率地同時評估大量心血管相關基因，因此越來越多的實驗室開始採用此類平台。生物資訊流程的改進提高了突變解讀的準確性，並降低了不同實驗室間報告結果的差異。技術開發人員不斷推出自動化和人工智慧（AI）驅動的分析工具，進一步提升了檢查室的工作效率。這些創新增強了臨床醫師的信心，並擴大了全面心臟基因檢測的覆蓋範圍。

將遺傳諮詢融入心血管醫學的進程正在推進。

有效解讀基因檢測結果需要在檢測前後進行專業諮詢。醫療系統日益認知到，多學科協作能夠提升臨床效用，並加深患者對其遺傳性心血管風險的理解。醫院正在將遺傳諮詢師納入其心血管疾病管理項目，以支持患者做出知情的檢測決策和長期的家庭管理。這種協作式醫療模式能夠提高病患的治療依從性，同時增強遺傳訊息的臨床價值。整合諮詢服務能夠減少複雜基因組檢測結果所帶來的不確定性，進而促進更廣泛的檢測。

市場限制因素

儘管臨床證據不斷增加，但部分醫療體系報銷範圍有限，限制了患者獲得全面的心臟基因檢測。解讀意義不明的突變仍然具有挑戰性，造成臨床上的不確定性，可能導致治療決策延誤，並需要額外的基因評估。訓練有素的臨床遺傳學家和遺傳諮詢師短缺，限制了檢測能力，並降低了精準心血管診療的效率。此外，對基因組資訊的資料隱私擔憂也可能影響病患和醫療服務提供者的接受度。

市場定義和範圍
心臟遺傳檢測概述
產業變化
主要市場趨勢
市場規模表現分析
市場預測
心血管遺傳疾病概述
疾病負擔與未滿足的臨床需求
流行病學和盛行率分析
已確診患者族群的分析
目前基因檢測實施的分析
心臟基因檢測的臨床效用
病人歷程分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新興技術
產品創新
臨床試驗分析
管道分析
將人工智慧應用於心臟基因檢測
與數位健康融合

第7章監理情勢

法律規範
核准流程
合規要求

第8章：心臟遺傳學檢測市場：展望分析

分析：按技術平台
分析：透過調查方法
分析：依生物標記類型
分析：依樣本類型
分析：透過臨床應用

第9章心臟遺傳學檢測市場：細分市場分析

按測試類型
- 診斷測試
- 預測性和無症狀檢測
- 基因帶原檢測
- 級聯測試
- 產前和胚胎著床前基因檢測
透過技術
- 次世代定序（NGS）
- 全EXOME定序（WES）
- 全基因測序（WGS）
- 標靶基因檢測
- 桑格定序
- 採用PCR方法進行檢測
- 染色體微陣列分析（CMA）
依疾病類型
- 遺傳性心肌病
  - 肥厚型心肌病（HCM）
  - 擴大性心肌病（DCM）
  - 心律不整性心肌病（ACM/ARVC）
  - 限制型心肌病（RCM）
- 遺傳性心律不整症候群
  - 長QT間期症候群
  - 布魯加達症候群
  - 兒茶酚胺多形性心室心搏過速（CPVT）
  - 短QT間期症候群
- 遺傳性主動脈疾病與結締組織疾病
  - 馬凡氏症候群
  - 洛伊斯-迪茨症候群
  - 血管型埃勒斯-當洛斯症候群
- 遺傳性高膽固醇症
- 其他遺傳性心血管疾病
依基因面板類型
- 單基因檢測
- 多基因檢測
- 全EXOME定序
- 全基因測序
依樣本類型
- 血
- 唾液/口腔黏膜拭子
- 組織和其他檢體
最終用戶
- 醫院
- 循環系統專科診所
- 診斷檢查室
- 學術研究機構

第10章：心臟遺傳學檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：心臟遺傳學檢測市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Eurofins Scientific SE
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings（Labcorp）
Invitae Corporation
Natera, Inc.
GeneDx Holdings Corp.
Centogene NV
Blueprint Genetics Oy
Ambry Genetics Corporation
Fulgent Genetics, Inc.
Exact Sciences Corporation（PreventionGenetics）
3billion Inc.
Myriad Genetics, Inc.

第14章：心臟遺傳學檢測市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009133

The Cardiogenetic Testing Market is forecast to grow at a CAGR of 11.9%, reaching USD 13.06 billion in 2031 from USD 4.76 billion in 2026.

The global cardiogenetic testing market is experiencing rapid expansion, driven by the growing integration of genomics into cardiovascular medicine and the increasing recognition of inherited cardiac disorders. Cardiogenetic testing identifies pathogenic genetic variants associated with inherited cardiovascular diseases including cardiomyopathies, inherited arrhythmia syndromes, familial hypercholesterolemia, and connective tissue disorders affecting the cardiovascular system. The market encompasses laboratory-developed tests, targeted gene panels, whole exome sequencing, whole genome sequencing, bioinformatics platforms, interpretation software, and genetic counseling services that collectively support clinical decision-making. Demand is increasing because cardiovascular specialists are recognizing that phenotypic assessment alone frequently cannot distinguish hereditary disease from acquired cardiac disorders. Earlier molecular confirmation supports personalized monitoring strategies, guides therapeutic interventions, and enables family-based cascade testing. Regulatory agencies and professional medical societies continue emphasizing standardized laboratory quality, analytical validity, and evidence-based clinical reporting, reinforcing confidence in genomic diagnostics. Healthcare providers increasingly integrate multidisciplinary genetic counseling with cardiovascular care, allowing test results to translate into long-term disease management rather than isolated diagnostic findings. This evolution strengthens the strategic importance of cardiogenetic testing within precision medicine programs worldwide.

Market Drivers

Expanding Clinical Adoption of Precision Cardiology

Precision cardiology integrates genomic information with conventional cardiovascular assessment to improve diagnosis and treatment selection. Healthcare providers are increasingly adopting genetic testing because inherited cardiovascular disorders often present with overlapping clinical features that complicate conventional diagnosis. Earlier molecular confirmation reduces diagnostic uncertainty while supporting personalized surveillance and therapeutic planning. Diagnostic laboratories are expanding specialized cardiovascular testing portfolios to address this growing clinical demand. The increasing incorporation of genomics into cardiovascular practice strengthens long-term adoption across tertiary hospitals and specialized cardiac centers.

Rising Demand for Family-Based Cascade Screening

Inherited cardiovascular disorders frequently affect multiple generations within the same family. Healthcare providers recommend cascade genetic testing because identifying pathogenic variants among relatives enables preventive monitoring before symptoms develop. Clinical awareness is increasing as professional societies emphasize family-based risk assessment for inherited cardiac diseases. Diagnostic laboratories are developing streamlined testing workflows that facilitate screening of multiple family members. Earlier identification of genetically predisposed individuals reduces disease burden through proactive clinical management.

Continuous Advancements in Sequencing Technologies

Sequencing technologies continue improving analytical sensitivity, throughput, and cost efficiency. Laboratories are increasingly implementing next-generation sequencing platforms because they simultaneously evaluate numerous cardiovascular genes with greater efficiency than sequential testing approaches. Improved bioinformatics pipelines enhance variant interpretation and reduce reporting variability across laboratories. Technology developers continue introducing automation and artificial intelligence-assisted analytical tools that improve laboratory productivity. These innovations strengthen confidence among clinicians and expand the accessibility of comprehensive cardiogenetic testing.

Increasing Integration of Genetic Counseling into Cardiovascular Care

Effective interpretation of genetic findings requires specialized counseling before and after testing. Healthcare systems increasingly recognize that multidisciplinary care improves clinical utility and patient understanding of inherited cardiovascular risk. Hospitals are integrating genetic counselors within cardiovascular programs to support informed testing decisions and long-term family management. This coordinated care model enhances patient adherence while improving the clinical value of genetic information. The integration of counseling services strengthens adoption by reducing uncertainty surrounding complex genomic findings.

Market Restraints

Limited reimbursement coverage across several healthcare systems continues restricting patient access to comprehensive cardiogenetic testing despite expanding clinical evidence. Interpretation of variants of uncertain significance remains challenging, creating clinical uncertainty that may delay treatment decisions and require additional genetic evaluation. Shortages of trained clinical geneticists and genetic counselors limit testing capacity and reduce the efficiency of precision cardiovascular care delivery. Additionally, data privacy concerns regarding genomic information can influence patient and provider acceptance.

Technology and Segment Insights

By Test Type

Diagnostic testing represents the largest application segment because it confirms the molecular basis of inherited cardiovascular disorders in symptomatic individuals. Healthcare providers are increasingly requesting comprehensive genetic evaluation when conventional clinical findings cannot distinguish between phenotypically similar diseases. Predictive and presymptomatic testing enables risk assessment for asymptomatic individuals with a family history of inherited cardiac conditions. Carrier testing identifies individuals carrying genetic variants for autosomal recessive or X-linked disorders. Cascade testing facilitates family-based screening after a pathogenic variant is identified in a proband. Prenatal and preimplantation genetic testing supports reproductive decision-making for couples at risk of passing on inherited cardiovascular disorders.

By Technology

Next-generation sequencing dominates the technology landscape because it enables simultaneous analysis of numerous cardiovascular genes with high analytical sensitivity. Laboratories are increasingly adopting NGS platforms as demand shifts toward comprehensive genomic evaluation. Whole exome sequencing and whole genome sequencing provide the broadest genomic coverage for complex or atypical presentations. Targeted gene panel testing offers a balanced approach between cost and comprehensiveness for specific disease categories. Sanger sequencing remains important for targeted variant confirmation and familial segregation analysis. PCR-based testing provides rapid analysis for specific mutations. Chromosomal microarray analysis detects copy number variations.

By Disorder Type

Inherited cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic cardiomyopathy, constitute a major clinical application because they frequently result from pathogenic variants affecting cardiac muscle structure and function. Inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia, represent another significant segment. Familial aortopathies and connective tissue disorders, including Marfan syndrome and Loeys-Dietz syndrome, are important indications. Familial hypercholesterolemia is a major segment driving testing for early identification and management of extreme lipid risk. Other inherited cardiovascular disorders contribute to the diversity of the market.

By End User

Hospitals and specialty cardiology clinics represent significant end-user segments, integrating genetic testing into cardiovascular care pathways. Diagnostic laboratories are the primary service providers, offering comprehensive testing panels and interpretation. Academic and research institutes contribute to test development and clinical validation.

Competitive and Strategic Outlook

The competitive landscape features major diagnostic and sequencing companies. F. Hoffmann-La Roche Ltd. maintains a strong strategic position through its integrated diagnostics portfolio, sequencing technologies, and global molecular diagnostics infrastructure. Illumina, Inc. remains the global leader in next-generation sequencing technologies, providing foundational platforms for numerous cardiogenetic testing laboratories. Eurofins Scientific SE operates one of the world's largest laboratory networks, providing comprehensive genetic testing services. Quest Diagnostics Incorporated and Laboratory Corporation of America Holdings (Labcorp) are leading diagnostic information service providers with extensive molecular and hereditary disease testing portfolios. Invitae Corporation has established a strong reputation in hereditary genetic testing with broad multi-gene panels. Natera, Inc. applies advanced cell-free DNA analysis and molecular diagnostics expertise. GeneDx Holdings Corp. specializes in rare disease and whole exome/genome sequencing diagnostics.
Strategic developments include increasing integration of artificial intelligence for variant interpretation, expansion of preventive genomic screening programs, and growth of personalized cardiovascular therapeutics. Companies are forming partnerships with healthcare providers, pharmaceutical companies, and research institutions to support biomarker discovery and precision medicine. Service expansions focus on comprehensive gene panels, advanced bioinformatics, and integrated genetic counseling. Companies that successfully combine advanced sequencing technologies, robust clinical interpretation, and scalable laboratory operations are expected to maintain competitive leadership.

Conclusion

The cardiogenetic testing market is poised for substantial growth, driven by the expanding clinical adoption of precision cardiology, advancements in sequencing technologies, and the increasing recognition of inherited cardiac disorders. The evolution toward comprehensive genomic testing supporting early diagnosis, family-based screening, and personalized management is reshaping cardiovascular care. Companies that successfully deliver integrated, clinically validated, and accessible genetic testing solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Cardiogenetic Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Overview of Cardiogenetic Testing
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2031)
3.7 Cardiovascular Genetic Disorders Overview
3.8 Disease Burden & Unmet Clinical Needs
3.9 Epidemiology & Prevalence Analysis
3.10 Diagnosed Patient Population Analysis
3.11 Genetic Testing Adoption Analysis
3.12 Clinical Utility of Cardiogenetic Testing
3.13 Patient Journey Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Cardiogenetic Testing
6.6 Digital Health Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Cardiogenetic Testing Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Testing Methodology
8.3 Analysis by Biomarker Type
8.4 Analysis by Sample Type
8.5 Analysis by Clinical Application

9. Cardiogenetic Testing Market Segment Analysis (2021-2031)

9.1 By Test Type
- 9.1.1 Diagnostic Testing
- 9.1.2 Predictive & Presymptomatic Testing
- 9.1.3 Carrier Testing
- 9.1.4 Cascade Testing
- 9.1.5 Prenatal & Preimplantation Genetic Testing
9.2 By Technology
- 9.2.1 Next-Generation Sequencing (NGS)
- 9.2.2 Whole Exome Sequencing (WES)
- 9.2.3 Whole Genome Sequencing (WGS)
- 9.2.4 Targeted Gene Panel Testing
- 9.2.5 Sanger Sequencing
- 9.2.6 PCR-Based Testing
- 9.2.7 Chromosomal Microarray Analysis (CMA)
9.3 By Disorder Type
- 9.3.1 Inherited Cardiomyopathies
  - 9.3.1.1 Hypertrophic Cardiomyopathy (HCM)
  - 9.3.1.2 Dilated Cardiomyopathy (DCM)
  - 9.3.1.3 Arrhythmogenic Cardiomyopathy (ACM/ARVC)
  - 9.3.1.4 Restrictive Cardiomyopathy (RCM)
- 9.3.2 Inherited Arrhythmia Syndromes
  - 9.3.2.1 Long QT Syndrome
  - 9.3.2.2 Brugada Syndrome
  - 9.3.2.3 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
  - 9.3.2.4 Short QT Syndrome
- 9.3.3 Familial Aortopathies & Connective Tissue Disorders
  - 9.3.3.1 Marfan Syndrome
  - 9.3.3.2 Loeys-Dietz Syndrome
  - 9.3.3.3 Vascular Ehlers-Danlos Syndrome
- 9.3.4 Familial Hypercholesterolemia
- 9.3.5 Other Inherited Cardiovascular Disorders
9.4 By Gene Panel Type
- 9.4.1 Single-Gene Testing
- 9.4.2 Multi-Gene Panel Testing
- 9.4.3 Whole Exome Sequencing
- 9.4.4 Whole Genome Sequencing
9.5 By Sample Type
- 9.5.1 Blood
- 9.5.2 Saliva/Buccal Swab
- 9.5.3 Tissue & Other Specimens
9.6 By End User
- 9.6.1 Hospitals
- 9.6.2 Specialty Cardiology Clinics
- 9.6.3 Diagnostic Laboratories
- 9.6.4 Academic & Research Institutes